Across jurisdictions, legal changes are impacting the pharmaceutical industry and how drug companies handle large and small patent litigation cases. Asia IP contacted Finnegan partner John D. Livingstone for his thoughts on how to handle high-profile cases.
Livingstone said, “In high-profile cases, one should plan from the start to manage the expectations of the client and the media. For example, even if the case appears strong, public comments should be tempered by the realization that the case might not turn out as well as expected because of facts or issues not yet uncovered. Thus, overly optimistic comments should be avoided in most instances.”
Award/Ranking
Five Finnegan Partners Named 2024 Leading Litigators in America by Lawdragon
October 30, 2023
Commentary
Behind the Case: How Finnegan Helped Eli Lilly Swerve a $176.5M Patent Headache
October 10, 2023
Award/Ranking
Finnegan Receives Tier 1 Benchmark Litigation Rankings; Nine Attorneys Named Litigation Stars
October 5, 2023
Press Release
Former Finnegan Attorneys Return to Expand IP Transactions Practice with In-House Experience
October 2, 2023
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.